Adagene, a Suzhou biopharma, has dosed the first patient in a US Phase I trial of its lead candidate, ADG-106, a fully human mAb targeting a novel epitope of CD137. At the same time, Adagene announced that China has approved an IND for ADG-106. The Phase I trial will test the drug as a single agent in patients with solid tumors and non-Hodgkin lymphoma. ADG-106 is the first Adagene candidate to begin clinical trials. In March of this year, Adagene raised $50 million in a Series C round to develop six oncology projects as they near clinical trials.
Source: China Biotoday
